nodes	percent_of_prediction	percent_of_DWPC	metapath
Suramin—F2—hepatic artery—bile duct cancer	0.175	0.32	CbGeAlD
Suramin—F2—portal vein—bile duct cancer	0.152	0.278	CbGeAlD
Suramin—SIRT5—Signaling events mediated by HDAC Class I—MBD2—bile duct cancer	0.0644	0.142	CbGpPWpGaD
Suramin—F2—gall bladder—bile duct cancer	0.0261	0.0477	CbGeAlD
Suramin—SIRT1—pancreas—bile duct cancer	0.0227	0.0416	CbGeAlD
Suramin—SIRT1—Signaling events mediated by HDAC Class I—MBD2—bile duct cancer	0.019	0.042	CbGpPWpGaD
Suramin—SIRT5—liver—bile duct cancer	0.0174	0.0319	CbGeAlD
Suramin—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—KRT19—bile duct cancer	0.0171	0.0376	CbGpPWpGaD
Suramin—P2RX4—liver—bile duct cancer	0.0165	0.0302	CbGeAlD
Suramin—SIRT1—p73 transcription factor network—RNF43—bile duct cancer	0.0161	0.0354	CbGpPWpGaD
Suramin—PLA2G2A—pancreas—bile duct cancer	0.0159	0.0291	CbGeAlD
Suramin—SIRT1—liver—bile duct cancer	0.0145	0.0265	CbGeAlD
Suramin—ARSA—liver—bile duct cancer	0.0143	0.0261	CbGeAlD
Suramin—SIRT1—Negative epigenetic regulation of rRNA expression—MBD2—bile duct cancer	0.0138	0.0303	CbGpPWpGaD
Suramin—SIRT5—lymph node—bile duct cancer	0.0134	0.0245	CbGeAlD
Suramin—RYR1—liver—bile duct cancer	0.0134	0.0245	CbGeAlD
Suramin—PLA2G2A—Glypican 1 network—TGFBR2—bile duct cancer	0.0128	0.0283	CbGpPWpGaD
Suramin—P2RX4—lymph node—bile duct cancer	0.0126	0.0232	CbGeAlD
Suramin—SIRT1—Epigenetic regulation of gene expression—MBD2—bile duct cancer	0.0122	0.0269	CbGpPWpGaD
Suramin—SIRT1—lymph node—bile duct cancer	0.0111	0.0203	CbGeAlD
Suramin—ARSA—lymph node—bile duct cancer	0.0109	0.02	CbGeAlD
Suramin—PLA2G2A—liver—bile duct cancer	0.0101	0.0185	CbGeAlD
Suramin—F2—Syndecan-4-mediated signaling events—TNC—bile duct cancer	0.00818	0.018	CbGpPWpGaD
Suramin—ARSA—Post-translational protein modification—MUC4—bile duct cancer	0.00812	0.0179	CbGpPWpGaD
Suramin—ARSA—Post-translational protein modification—MUC1—bile duct cancer	0.00812	0.0179	CbGpPWpGaD
Suramin—PLA2G2A—lymph node—bile duct cancer	0.00776	0.0142	CbGeAlD
Suramin—F2—liver—bile duct cancer	0.00764	0.014	CbGeAlD
Suramin—ARSA—Metabolism of lipids and lipoproteins—FAR2—bile duct cancer	0.00756	0.0167	CbGpPWpGaD
Suramin—PLA2G2A—Eicosanoid Synthesis—PTGS2—bile duct cancer	0.00709	0.0156	CbGpPWpGaD
Suramin—SIRT1—Androgen receptor signaling pathway—SMAD4—bile duct cancer	0.00632	0.0139	CbGpPWpGaD
Suramin—FSHR—G alpha (s) signalling events—GNAS—bile duct cancer	0.00618	0.0136	CbGpPWpGaD
Suramin—ARSA—Post-translational protein modification—MUC2—bile duct cancer	0.00615	0.0136	CbGpPWpGaD
Suramin—SIRT1—Regulation of retinoblastoma protein—MET—bile duct cancer	0.00615	0.0135	CbGpPWpGaD
Suramin—PLA2G4A—lymph node—bile duct cancer	0.0054	0.00988	CbGeAlD
Suramin—RYR1—Calcium Regulation in the Cardiac Cell—GNAS—bile duct cancer	0.00488	0.0108	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism of lipids and lipoproteins—FAR2—bile duct cancer	0.00487	0.0107	CbGpPWpGaD
Suramin—PLA2G2A—Glypican 1 network—TGFB1—bile duct cancer	0.00481	0.0106	CbGpPWpGaD
Suramin—F2—Regulation of IGF Activity by IGFBP—MMP2—bile duct cancer	0.00474	0.0105	CbGpPWpGaD
Suramin—RYR1—Myometrial Relaxation and Contraction Pathways—GNAS—bile duct cancer	0.00473	0.0104	CbGpPWpGaD
Suramin—SIRT1—Integrated Breast Cancer Pathway—TGFBR2—bile duct cancer	0.00437	0.00964	CbGpPWpGaD
Suramin—SIRT1—Integrated Breast Cancer Pathway—SMAD4—bile duct cancer	0.00414	0.00912	CbGpPWpGaD
Suramin—SIRT1—Signaling events mediated by HDAC Class III—TP53—bile duct cancer	0.00398	0.00878	CbGpPWpGaD
Suramin—ARSA—Metabolism of proteins—MUC4—bile duct cancer	0.00385	0.00848	CbGpPWpGaD
Suramin—ARSA—Metabolism of proteins—MUC1—bile duct cancer	0.00385	0.00848	CbGpPWpGaD
Suramin—SIRT1—Integrated Pancreatic Cancer Pathway—SMAD4—bile duct cancer	0.00343	0.00756	CbGpPWpGaD
Suramin—ARSA—Metabolism—FAR2—bile duct cancer	0.00337	0.00742	CbGpPWpGaD
Suramin—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—NOS2—bile duct cancer	0.00336	0.0074	CbGpPWpGaD
Suramin—F2—IL1 and megakaryotyces in obesity—MMP9—bile duct cancer	0.0032	0.00706	CbGpPWpGaD
Suramin—ARSA—Metabolism of lipids and lipoproteins—IDH1—bile duct cancer	0.00318	0.007	CbGpPWpGaD
Suramin—ARSA—Metabolism of proteins—MUC2—bile duct cancer	0.00292	0.00643	CbGpPWpGaD
Suramin—PLA2G4A—Prostaglandin Synthesis and Regulation—PTGS2—bile duct cancer	0.0028	0.00616	CbGpPWpGaD
Suramin—PLA2G2A—Spinal Cord Injury—NOS2—bile duct cancer	0.0027	0.00594	CbGpPWpGaD
Suramin—F2—Post-translational protein modification—MUC1—bile duct cancer	0.00269	0.00594	CbGpPWpGaD
Suramin—F2—Post-translational protein modification—MUC4—bile duct cancer	0.00269	0.00594	CbGpPWpGaD
Suramin—PLA2G2A—Cardiac Hypertrophic Response—TGFB1—bile duct cancer	0.00264	0.00582	CbGpPWpGaD
Suramin—F2—Syndecan-4-mediated signaling events—MMP9—bile duct cancer	0.00255	0.00561	CbGpPWpGaD
Suramin—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—PTGS2—bile duct cancer	0.00247	0.00544	CbGpPWpGaD
Suramin—SIRT1—Androgen receptor signaling pathway—EGFR—bile duct cancer	0.00245	0.0054	CbGpPWpGaD
Suramin—SIRT1—Circadian rythm related genes—NOS2—bile duct cancer	0.00245	0.0054	CbGpPWpGaD
Suramin—PLA2G4A—Platelet homeostasis—GNAS—bile duct cancer	0.00242	0.00534	CbGpPWpGaD
Suramin—F2—Angiopoietin receptor Tie2-mediated signaling—MMP2—bile duct cancer	0.00237	0.00522	CbGpPWpGaD
Suramin—P2RY2—GPCR ligand binding—GNAS—bile duct cancer	0.00232	0.00512	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism of lipids and lipoproteins—FAR2—bile duct cancer	0.0023	0.00506	CbGpPWpGaD
Suramin—FSHR—GPCR ligand binding—GNAS—bile duct cancer	0.00224	0.00494	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—FAR2—bile duct cancer	0.00217	0.00478	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism of lipids and lipoproteins—IDH1—bile duct cancer	0.00205	0.00451	CbGpPWpGaD
Suramin—RYR1—Transmembrane transport of small molecules—SLC5A5—bile duct cancer	0.00204	0.0045	CbGpPWpGaD
Suramin—F2—Post-translational protein modification—MUC2—bile duct cancer	0.00204	0.0045	CbGpPWpGaD
Suramin—SIRT1—Gene Expression—MBD2—bile duct cancer	0.00204	0.0045	CbGpPWpGaD
Suramin—PLA2G4A—AGE/RAGE pathway—NOS2—bile duct cancer	0.00202	0.00446	CbGpPWpGaD
Suramin—PLA2G2A—Spinal Cord Injury—PTGS2—bile duct cancer	0.00198	0.00437	CbGpPWpGaD
Suramin—SIRT1—Integrated Pancreatic Cancer Pathway—ERBB2—bile duct cancer	0.00192	0.00423	CbGpPWpGaD
Suramin—PLA2G2A—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—bile duct cancer	0.00188	0.00415	CbGpPWpGaD
Suramin—SIRT1—Integrated Pancreatic Cancer Pathway—PTGS2—bile duct cancer	0.00188	0.00414	CbGpPWpGaD
Suramin—PLA2G4A—Arachidonic acid metabolism—PTGS2—bile duct cancer	0.00186	0.00409	CbGpPWpGaD
Suramin—PLA2G4A—Platelet homeostasis—NOS2—bile duct cancer	0.00177	0.0039	CbGpPWpGaD
Suramin—PLA2G2A—Spinal Cord Injury—MMP9—bile duct cancer	0.00174	0.00383	CbGpPWpGaD
Suramin—PLA2G4A—AGE/RAGE pathway—MMP2—bile duct cancer	0.00174	0.00382	CbGpPWpGaD
Suramin—P2RY2—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—bile duct cancer	0.00172	0.00379	CbGpPWpGaD
Suramin—ARSA—Metabolism—IDH2—bile duct cancer	0.00164	0.00362	CbGpPWpGaD
Suramin—SIRT1—Integrated Breast Cancer Pathway—EGFR—bile duct cancer	0.00161	0.00354	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—RNF43—bile duct cancer	0.0016	0.00352	CbGpPWpGaD
Suramin—RYR1—Transmembrane transport of small molecules—GNAS—bile duct cancer	0.00159	0.0035	CbGpPWpGaD
Suramin—P2RY2—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bile duct cancer	0.00157	0.00346	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—RNF43—bile duct cancer	0.00154	0.0034	CbGpPWpGaD
Suramin—SIRT1—Integrated Breast Cancer Pathway—KRAS—bile duct cancer	0.00152	0.00334	CbGpPWpGaD
Suramin—P2RY2—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—bile duct cancer	0.00148	0.00326	CbGpPWpGaD
Suramin—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—TP53—bile duct cancer	0.00147	0.00324	CbGpPWpGaD
Suramin—PLA2G4A—p38 MAPK Signaling Pathway—HRAS—bile duct cancer	0.00144	0.00317	CbGpPWpGaD
Suramin—PLA2G2A—Spinal Cord Injury—TGFB1—bile duct cancer	0.00143	0.00316	CbGpPWpGaD
Suramin—ARSA—Metabolism—IDH1—bile duct cancer	0.00141	0.00312	CbGpPWpGaD
Suramin—PLA2G2A—Spinal Cord Injury—EGFR—bile duct cancer	0.00141	0.0031	CbGpPWpGaD
Suramin—RYR1—Myometrial Relaxation and Contraction Pathways—IL6—bile duct cancer	0.00138	0.00305	CbGpPWpGaD
Suramin—SIRT1—Integrated Pancreatic Cancer Pathway—TGFB1—bile duct cancer	0.00136	0.00299	CbGpPWpGaD
Suramin—SIRT1—Integrated Breast Cancer Pathway—TP53—bile duct cancer	0.00135	0.00297	CbGpPWpGaD
Suramin—SIRT1—Integrated Pancreatic Cancer Pathway—EGFR—bile duct cancer	0.00133	0.00293	CbGpPWpGaD
Suramin—P2RY2—GPCR downstream signaling—GNAS—bile duct cancer	0.00131	0.00289	CbGpPWpGaD
Suramin—PLA2G4A—AGE/RAGE pathway—MMP9—bile duct cancer	0.0013	0.00287	CbGpPWpGaD
Suramin—F2—Selenium Micronutrient Network—PTGS2—bile duct cancer	0.00129	0.00285	CbGpPWpGaD
Suramin—PLA2G4A—PDGF Pathway—HRAS—bile duct cancer	0.00129	0.00284	CbGpPWpGaD
Suramin—F2—Metabolism of proteins—MUC4—bile duct cancer	0.00128	0.00282	CbGpPWpGaD
Suramin—F2—Metabolism of proteins—MUC1—bile duct cancer	0.00128	0.00282	CbGpPWpGaD
Suramin—FSHR—GPCR downstream signaling—GNAS—bile duct cancer	0.00127	0.00279	CbGpPWpGaD
Suramin—P2RY2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—bile duct cancer	0.00126	0.00277	CbGpPWpGaD
Suramin—SIRT1—Integrated Pancreatic Cancer Pathway—KRAS—bile duct cancer	0.00126	0.00277	CbGpPWpGaD
Suramin—P2RY2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—bile duct cancer	0.00121	0.00266	CbGpPWpGaD
Suramin—P2RY2—Signaling by GPCR—GNAS—bile duct cancer	0.00119	0.00263	CbGpPWpGaD
Suramin—PLA2G2A—Spinal Cord Injury—TP53—bile duct cancer	0.00118	0.0026	CbGpPWpGaD
Suramin—PLA2G4A—Integrated Pancreatic Cancer Pathway—SMAD4—bile duct cancer	0.00116	0.00256	CbGpPWpGaD
Suramin—FSHR—Signaling by GPCR—GNAS—bile duct cancer	0.00115	0.00254	CbGpPWpGaD
Suramin—SIRT1—Integrated Pancreatic Cancer Pathway—TP53—bile duct cancer	0.00112	0.00246	CbGpPWpGaD
Suramin—F2—Platelet activation, signaling and aggregation—HGF—bile duct cancer	0.0011	0.00242	CbGpPWpGaD
Suramin—F2—Vitamin B12 Metabolism—IL6—bile duct cancer	0.00109	0.0024	CbGpPWpGaD
Suramin—PLA2G2A—Spinal Cord Injury—IL6—bile duct cancer	0.00108	0.00238	CbGpPWpGaD
Suramin—SIRT1—Circadian rythm related genes—TP53—bile duct cancer	0.00107	0.00236	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—IDH2—bile duct cancer	0.00106	0.00234	CbGpPWpGaD
Suramin—PLA2G4A—AGE/RAGE pathway—EGFR—bile duct cancer	0.00105	0.00232	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—FAR2—bile duct cancer	0.00102	0.00225	CbGpPWpGaD
Suramin—PLA2G4A—Platelet activation, signaling and aggregation—HGF—bile duct cancer	0.001	0.00221	CbGpPWpGaD
Suramin—SIRT1—Circadian rythm related genes—IL6—bile duct cancer	0.000982	0.00216	CbGpPWpGaD
Suramin—F2—Metabolism of proteins—MUC2—bile duct cancer	0.000969	0.00213	CbGpPWpGaD
Suramin—F2—Folate Metabolism—TP53—bile duct cancer	0.000968	0.00213	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism of lipids and lipoproteins—IDH1—bile duct cancer	0.000964	0.00212	CbGpPWpGaD
Suramin—ARSA—Metabolism—SLC5A5—bile duct cancer	0.000933	0.00206	CbGpPWpGaD
Suramin—F2—Cell surface interactions at the vascular wall—NRAS—bile duct cancer	0.000915	0.00202	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—IDH1—bile duct cancer	0.000911	0.00201	CbGpPWpGaD
Suramin—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—HRAS—bile duct cancer	0.000902	0.00199	CbGpPWpGaD
Suramin—F2—Folate Metabolism—IL6—bile duct cancer	0.000886	0.00195	CbGpPWpGaD
Suramin—ARSA—Metabolism of proteins—MMP2—bile duct cancer	0.000882	0.00194	CbGpPWpGaD
Suramin—PLA2G4A—Endothelins—HRAS—bile duct cancer	0.000879	0.00194	CbGpPWpGaD
Suramin—ARSA—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	0.000874	0.00193	CbGpPWpGaD
Suramin—SIRT1—Cellular responses to stress—TP53—bile duct cancer	0.000863	0.0019	CbGpPWpGaD
Suramin—SIRT1—Gene Expression—SMAD4—bile duct cancer	0.000821	0.00181	CbGpPWpGaD
Suramin—SIRT1—Cellular responses to stress—IL6—bile duct cancer	0.00079	0.00174	CbGpPWpGaD
Suramin—F2—Cell surface interactions at the vascular wall—KRAS—bile duct cancer	0.000787	0.00173	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—TGFBR2—bile duct cancer	0.00073	0.00161	CbGpPWpGaD
Suramin—ARSA—Metabolism—GNAS—bile duct cancer	0.000725	0.0016	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—TGFBR2—bile duct cancer	0.000705	0.00155	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—GNAS—bile duct cancer	0.000704	0.00155	CbGpPWpGaD
Suramin—F2—Selenium Micronutrient Network—IL6—bile duct cancer	0.000704	0.00155	CbGpPWpGaD
Suramin—PLA2G4A—PDGFR-beta signaling pathway—NRAS—bile duct cancer	0.000694	0.00153	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—SMAD4—bile duct cancer	0.000691	0.00152	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—GNAS—bile duct cancer	0.00068	0.0015	CbGpPWpGaD
Suramin—F2—Cell surface interactions at the vascular wall—HRAS—bile duct cancer	0.000669	0.00147	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—SMAD4—bile duct cancer	0.000667	0.00147	CbGpPWpGaD
Suramin—F2—GPCR ligand binding—GNAS—bile duct cancer	0.000664	0.00146	CbGpPWpGaD
Suramin—F2—Regulation of Actin Cytoskeleton—NRAS—bile duct cancer	0.00066	0.00145	CbGpPWpGaD
Suramin—PLA2G4A—Integrated Pancreatic Cancer Pathway—ERBB2—bile duct cancer	0.00065	0.00143	CbGpPWpGaD
Suramin—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTGS2—bile duct cancer	0.000636	0.0014	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—SLC5A5—bile duct cancer	0.000601	0.00132	CbGpPWpGaD
Suramin—F2—Regulation of Actin Cytoskeleton—EGFR—bile duct cancer	0.000601	0.00132	CbGpPWpGaD
Suramin—PLA2G4A—PDGFR-beta signaling pathway—KRAS—bile duct cancer	0.000598	0.00132	CbGpPWpGaD
Suramin—F2—Hemostasis—GNAS—bile duct cancer	0.000594	0.00131	CbGpPWpGaD
Suramin—F2—Regulation of Actin Cytoskeleton—KRAS—bile duct cancer	0.000568	0.00125	CbGpPWpGaD
Suramin—F2—Hemostasis—HGF—bile duct cancer	0.000566	0.00125	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	0.000563	0.00124	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—GNAS—bile duct cancer	0.000543	0.0012	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—HGF—bile duct cancer	0.000517	0.00114	CbGpPWpGaD
Suramin—PLA2G4A—PDGFR-beta signaling pathway—HRAS—bile duct cancer	0.000508	0.00112	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—IDH2—bile duct cancer	0.000499	0.0011	CbGpPWpGaD
Suramin—P2RY2—Signaling by GPCR—NRAS—bile duct cancer	0.000498	0.0011	CbGpPWpGaD
Suramin—F2—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—bile duct cancer	0.000492	0.00108	CbGpPWpGaD
Suramin—FSHR—Signaling by GPCR—NRAS—bile duct cancer	0.000481	0.00106	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—GNAS—bile duct cancer	0.000467	0.00103	CbGpPWpGaD
Suramin—PLA2G4A—Integrated Pancreatic Cancer Pathway—TGFB1—bile duct cancer	0.00046	0.00101	CbGpPWpGaD
Suramin—F2—Signaling Pathways—RNF43—bile duct cancer	0.000457	0.00101	CbGpPWpGaD
Suramin—P2RY2—Signaling by GPCR—EGFR—bile duct cancer	0.000454	0.001	CbGpPWpGaD
Suramin—PLA2G4A—Integrated Pancreatic Cancer Pathway—EGFR—bile duct cancer	0.000451	0.000993	CbGpPWpGaD
Suramin—F2—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bile duct cancer	0.000448	0.000987	CbGpPWpGaD
Suramin—F2—Platelet activation, signaling and aggregation—TGFB1—bile duct cancer	0.000447	0.000985	CbGpPWpGaD
Suramin—FSHR—Signaling by GPCR—EGFR—bile duct cancer	0.000438	0.000966	CbGpPWpGaD
Suramin—F2—Hemostasis—NOS2—bile duct cancer	0.000434	0.000955	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—IDH1—bile duct cancer	0.000429	0.000946	CbGpPWpGaD
Suramin—P2RY2—Signaling by GPCR—KRAS—bile duct cancer	0.000429	0.000945	CbGpPWpGaD
Suramin—PLA2G4A—Integrated Pancreatic Cancer Pathway—KRAS—bile duct cancer	0.000426	0.000938	CbGpPWpGaD
Suramin—F2—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—bile duct cancer	0.000423	0.000933	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—RNF43—bile duct cancer	0.000418	0.00092	CbGpPWpGaD
Suramin—FSHR—Signaling by GPCR—KRAS—bile duct cancer	0.000414	0.000912	CbGpPWpGaD
Suramin—PLA2G4A—Platelet activation, signaling and aggregation—TGFB1—bile duct cancer	0.000409	0.000901	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—NOS2—bile duct cancer	0.000397	0.000874	CbGpPWpGaD
Suramin—ARSA—Metabolism—PTGS2—bile duct cancer	0.000389	0.000858	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—ERBB2—bile duct cancer	0.000387	0.000852	CbGpPWpGaD
Suramin—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—bile duct cancer	0.000378	0.000834	CbGpPWpGaD
Suramin—F2—GPCR downstream signaling—GNAS—bile duct cancer	0.000375	0.000827	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—ERBB2—bile duct cancer	0.000374	0.000823	CbGpPWpGaD
Suramin—P2RY2—Signaling by GPCR—HRAS—bile duct cancer	0.000364	0.000803	CbGpPWpGaD
Suramin—F2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—bile duct cancer	0.00036	0.000793	CbGpPWpGaD
Suramin—FSHR—Signaling by GPCR—HRAS—bile duct cancer	0.000352	0.000776	CbGpPWpGaD
Suramin—P2RY2—Signaling by GPCR—IL6—bile duct cancer	0.000349	0.000769	CbGpPWpGaD
Suramin—F2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—bile duct cancer	0.000344	0.000759	CbGpPWpGaD
Suramin—F2—Signaling by GPCR—GNAS—bile duct cancer	0.000341	0.000751	CbGpPWpGaD
Suramin—FSHR—Signaling by GPCR—IL6—bile duct cancer	0.000337	0.000742	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—MMP9—bile duct cancer	0.000332	0.000731	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—MMP9—bile duct cancer	0.00032	0.000706	CbGpPWpGaD
Suramin—PLA2G4A—Signaling by GPCR—GNAS—bile duct cancer	0.000312	0.000687	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—NRAS—bile duct cancer	0.000294	0.000648	CbGpPWpGaD
Suramin—F2—Metabolism of proteins—MMP2—bile duct cancer	0.000293	0.000645	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—NRAS—bile duct cancer	0.000284	0.000626	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—SLC5A5—bile duct cancer	0.000283	0.000624	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—TGFB1—bile duct cancer	0.000273	0.000602	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—EGFR—bile duct cancer	0.000268	0.000591	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	0.000265	0.000585	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—TGFB1—bile duct cancer	0.000264	0.000582	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—EGFR—bile duct cancer	0.000259	0.000571	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—KRAS—bile duct cancer	0.000253	0.000558	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—PTGS2—bile duct cancer	0.000251	0.000553	CbGpPWpGaD
Suramin—F2—Hemostasis—NRAS—bile duct cancer	0.000248	0.000547	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—KRAS—bile duct cancer	0.000245	0.000539	CbGpPWpGaD
Suramin—F2—Hemostasis—TGFB1—bile duct cancer	0.000231	0.000508	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—NRAS—bile duct cancer	0.000227	0.0005	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—TP53—bile duct cancer	0.000225	0.000496	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—GNAS—bile duct cancer	0.00022	0.000485	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—TP53—bile duct cancer	0.000217	0.000479	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—HRAS—bile duct cancer	0.000215	0.000474	CbGpPWpGaD
Suramin—F2—Hemostasis—KRAS—bile duct cancer	0.000214	0.00047	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—TGFB1—bile duct cancer	0.000211	0.000464	CbGpPWpGaD
Suramin—F2—Signaling Pathways—TGFBR2—bile duct cancer	0.000209	0.00046	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—HRAS—bile duct cancer	0.000208	0.000458	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—IL6—bile duct cancer	0.000206	0.000454	CbGpPWpGaD
Suramin—F2—Signaling Pathways—GNAS—bile duct cancer	0.000201	0.000443	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—IL6—bile duct cancer	0.000199	0.000438	CbGpPWpGaD
Suramin—F2—Signaling Pathways—SMAD4—bile duct cancer	0.000197	0.000435	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—KRAS—bile duct cancer	0.000195	0.00043	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—TGFBR2—bile duct cancer	0.000191	0.00042	CbGpPWpGaD
Suramin—F2—Hemostasis—TP53—bile duct cancer	0.00019	0.000418	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—GNAS—bile duct cancer	0.000184	0.000406	CbGpPWpGaD
Suramin—F2—Hemostasis—HRAS—bile duct cancer	0.000181	0.0004	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—SMAD4—bile duct cancer	0.000181	0.000398	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—TP53—bile duct cancer	0.000174	0.000382	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—HRAS—bile duct cancer	0.000166	0.000366	CbGpPWpGaD
Suramin—F2—Signaling by GPCR—NRAS—bile duct cancer	0.000142	0.000314	CbGpPWpGaD
Suramin—PLA2G4A—Signaling by GPCR—NRAS—bile duct cancer	0.00013	0.000287	CbGpPWpGaD
Suramin—F2—Signaling by GPCR—EGFR—bile duct cancer	0.00013	0.000286	CbGpPWpGaD
Suramin—F2—Signaling by GPCR—KRAS—bile duct cancer	0.000123	0.00027	CbGpPWpGaD
Suramin—PLA2G4A—Signaling by GPCR—EGFR—bile duct cancer	0.000119	0.000261	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—PTGS2—bile duct cancer	0.000118	0.00026	CbGpPWpGaD
Suramin—PLA2G4A—Signaling by GPCR—KRAS—bile duct cancer	0.000112	0.000247	CbGpPWpGaD
Suramin—F2—Signaling Pathways—ERBB2—bile duct cancer	0.000111	0.000244	CbGpPWpGaD
Suramin—F2—Signaling by GPCR—HRAS—bile duct cancer	0.000104	0.000229	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—ERBB2—bile duct cancer	0.000101	0.000223	CbGpPWpGaD
Suramin—F2—Signaling by GPCR—IL6—bile duct cancer	9.97e-05	0.00022	CbGpPWpGaD
Suramin—PLA2G4A—Signaling by GPCR—HRAS—bile duct cancer	9.53e-05	0.00021	CbGpPWpGaD
Suramin—F2—Signaling Pathways—MMP9—bile duct cancer	9.48e-05	0.000209	CbGpPWpGaD
Suramin—PLA2G4A—Signaling by GPCR—IL6—bile duct cancer	9.12e-05	0.000201	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—MMP9—bile duct cancer	8.67e-05	0.000191	CbGpPWpGaD
Suramin—F2—Signaling Pathways—NRAS—bile duct cancer	8.41e-05	0.000185	CbGpPWpGaD
Suramin—F2—Signaling Pathways—TGFB1—bile duct cancer	7.81e-05	0.000172	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—NRAS—bile duct cancer	7.69e-05	0.000169	CbGpPWpGaD
Suramin—F2—Signaling Pathways—EGFR—bile duct cancer	7.66e-05	0.000169	CbGpPWpGaD
Suramin—F2—Signaling Pathways—KRAS—bile duct cancer	7.24e-05	0.000159	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—TGFB1—bile duct cancer	7.15e-05	0.000157	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—EGFR—bile duct cancer	7.01e-05	0.000154	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—KRAS—bile duct cancer	6.62e-05	0.000146	CbGpPWpGaD
Suramin—F2—Signaling Pathways—TP53—bile duct cancer	6.43e-05	0.000142	CbGpPWpGaD
Suramin—F2—Signaling Pathways—HRAS—bile duct cancer	6.15e-05	0.000136	CbGpPWpGaD
Suramin—F2—Signaling Pathways—IL6—bile duct cancer	5.89e-05	0.00013	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—TP53—bile duct cancer	5.88e-05	0.00013	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—HRAS—bile duct cancer	5.63e-05	0.000124	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—IL6—bile duct cancer	5.39e-05	0.000119	CbGpPWpGaD
